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Abstract:  25 
Second generation antipsychotics (SGAs), notably atypical antipsychotics including olanzapine, 26 
clozapine and risperidone, can cause weight gain and obesity side effects. Antagonism of serotonin 27 
2c receptors (5-HT2cR) and activation of ghrelin receptor type 1a (GHSR1a) signalling have been 28 
identified as a main cause of SGA induced obesity. Here we review the pivotal regulatory role of 29 
the 5-HT2cR in ghrelin-mediated appetite signalling. The 5-HT2cR dimerizes with GHSR1a to 30 
inhibit orexigenic signalling, while 5-HT2cR antagonism reduces dimerization and increases 31 
GHSR1a-induced food intake. Dimerization is specific to the unedited 5-HT2cR isoform. 5-HT2cR 32 
antagonism by SGAs may disrupt the normal inhibitory tone on the GHSR1a, increasing orexigenic 33 
signalling. The 5-HT2cR and its interaction with the GHSR1a could serve as the basis for 34 
discovering novel approaches to preventing and treating SGA-induced obesity.   35 
Keywords: serotonin 2c receptors (5-HT2cR), ghrelin receptor type 1a (GHSR1a), heterodimer, 36 
antipsychotic drug-induced obesity 37 
 38 
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1. Atypical antipsychotic-induced obesity 41 
Antipsychotic medication is commonly used in the clinic to treat schizophrenia, bipolar disorder 42 
and other psychotic disorders. Despite more than a decade of scientific research, the side-effect of 43 
obesity caused by current second generation antipsychotics (SGAs) remains unresolved. Indeed, the 44 
prevalence of weight gain side-effects caused by SGAs range from 42 – 64% of treated patients [1-45 
3]. In long-term (≥48 weeks) studies of olanzapine, the mean weight gain is 5.6 kg [1]. 46 
Understandably, weight gain side-effects are strong predictors of medication non-compliance, 47 
which is a primary barrier to the effective treatment of these serious psychiatric illnesses [4, 5]. 48 
Medication non-compliance is particularly problematic due to the astounding 5-fold increased risk 49 
of symptom relapse, hospitalisation and negative long-term outcomes [6, 7]. In addition, the 50 
relationship between obesity and antipsychotic drug use has been reported in the adult population 51 
through a longitudinal, retrospective claim database study [8]. The Clinical Antipsychotic Trials of 52 
Intervention Effectiveness (CATIE) trial revealed average body mass indexes (kg/m
2
) of 33.0±8.1 53 
in female and 28.5 ± 6.2 in male schizophrenia patients with a history of chronic antipsychotic drug 54 
treatment [3]. Furthermore, the prevalence of metabolic syndrome is reportedly 52% and 36% of 55 
female and male schizophrenia patients, respectively [3]. Obesity and metabolic syndrome are 56 
serious risk factors for further chronic illnesses, such as dyslipidaemia, type 2 diabetes mellitus, 57 
cardiovascular disease and stroke, which are major global health concerns. These health issues 58 
highlight the urgency of understanding the mechanisms underlying SGA-induced body weight gain 59 
and obesity.  60 
 61 
SGA-induced obesity is caused by over-eating, decreased energy expenditure and altered energy 62 
metabolism [9-11]. For example, a randomized double-blind study reported increased food craving 63 
with olanzapine and clozapine treatment [9], and a low resting energy expenditure was identified in 64 
SGA-treated male patients [10]. Furthermore, in female animal studies, olanzapine increases food 65 
intake and reduces temperature and thermogenesis in brown adipose tissue (BAT) [12, 13]. 66 
Numerous factors in the brain and peripheral tissues that regulate appetite, metabolism and body 67 
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weight can be dysregulated by SGA treatment. SGAs directly interact with a range of 68 
neurotransmitter receptors that are involved in energy homeostasis, such as 5-HT subtypes 2C 69 
(5HT-2cR) and 2A, histaminergic H1 receptor, adrenergic α, muscarinic M3 and dopaminergic D2 70 
receptors. In clinical and rodent studies, SGAs increase circulating ghrelin levels [14]. Moreover, 71 
rats treated with olanzapine have significantly elevated expression of the hypothalamic ghrelin 72 
receptor (also called growth hormone secretagogue receptor 1a; GHS-R1a) [14, 15]. There is a 73 
growing body of evidence to suggest a key regulatory role for the serotonin 5-HT2cR in GHSR1a 74 
signalling. It was recently identified that the 5-HT2cR interacts with the GHSR1a, forming a 75 
heterodimer that inhibits ghrelin signalling [16, 17]. This review explores the role of central 5-76 
HT2cR antagonism and GHSR1a molecular pathways in SGA-induced obesity. 77 
 78 
2. Hypothalamic Ghrelin-GHSR1a-NPY/AgRP Pathway in Body Weight Control and 79 
Obesity 80 
2.1 Ghrelin-GHSR1a-NPY/AgRP Pathway: Ghrelin is primarily produced by endocrine cells 81 
(X/A-like cells) in the gastric mucosa of humans and rodents [18]. It is the only known peripheral 82 
orexigenic hormone that increases food intake and body weight through actions on the 83 
hypothalamus. Central administration of ghrelin increases food intake, up-regulates lipogenic 84 
enzyme expression in adipocytes, and decreases thermogenesis-related mitochondrial uncoupling 85 
proteins in brown adipose tissue through activation of GHSR1a pathways in the hypothalamus [19, 86 
20]. For example, the intracerebroventricular (i.c.v.) administration of ghrelin rapidly increases 87 
feeding and this orexigenic effect is sustained for 24 hours in rats [19]. Ghrelin (i.c.v.) markedly up-88 
regulates lipogenic enzyme expression and mRNA levels of the fat storage–promoting enzymes 89 
lipoprotein lipase (LPL), acetyl-CoA carboxylase α (ACC), fatty acid synthase (FAS), and stearoyl-90 
CoA desaturase–1 (SCD1) in white adipose tissue (WAT) of rats [20]. Ghrelin (i.c.v) also markedly 91 
decreases the expression of thermogenesis-related mitochondrial uncoupling protein 1 (UCP1) in 92 
BAT of rats during both ad libitum and pair-feeding dietary paradigms [20]. Concerning the 93 
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mechanisms by which central ghrelin infusion modulates peripheral adipocyte metabolism, several 94 
lines of evidence suggest a role for the autonomic nervous system, as WAT and BAT are mostly 95 
innervated by the sympathetic nervous system [21, 22], and ghrelin-induced changes in adipocyte 96 
metabolism fail to occur in TKO (triple β1-, β2-, and β3-adrenoceptor knockout) mice lacking 97 
sympathetic nervous system signalling [20]. 98 
 99 
Endogenous ghrelin targets GHSR1a in the hypothalamic arcuate nucleus (Arc) through the blood 100 
brain barrier of the adjacent medial eminence [23]. In the Arc, more than 90% neuropeptide Y 101 
(NPY)/agouti-related peptide (AgRP) neurons express GHSR1a; however, only 8% pro-102 
opiomelanocortin (POMC) neurons express GHSR1a [24]. Activation of the GHSR1a stimulates 103 
food intake and fat deposition primarily through intracellular signalling pathways that increase 104 
orexigenic NPY and AgRP, and suppress anorexigenic POMC signalling in the hypothalamus [23, 105 
25, 26]. Therefore, there is an important regulatory role for the hypothalamic GHSR1a in metabolic 106 
homeostasis through its effects on orexigenic NPY/AgRP, appetite and body weight. Interestingly, 107 
olanzapine upregulates GHSR1a, NPY and AgRP in the Arc, suggesting that GHSR1 signaling in 108 
hypothalamic NPY and AgRP neurons are involved in the SGA-induced elevation of food intake 109 
[27]. 110 
 111 
2.2 The GHSR1a Intracellular Signalling Pathway (GHSR1a-AMPK-NPY/AgRP): The 112 
GHSR1a stimulates several signalling pathways [14]; however, research has highlighted an 113 
important role for the 5’ AMP-activated protein kinase (AMPK) pathway in ghrelin-induced food 114 
intake via NPY and AgRP up-regulation. For example, ghrelin increases hypothalamic AMPK in 115 
rodents in-vivo and in NPY neurons in-vitro, GHSR1a knock-out mice do not exhibit ghrelin-116 
induced hypothalamic AMPK activation or hyperphagia, while AMPK inhibition decreases ghrelin-117 
stimulated food intake [26]. The intracellular signalling pathway stimulated by the GHSR1a and 118 
AMPK is shown in Figure 1. Briefly, GHSR1a activation promotes mitochondrial β-oxidation 119 
through AMPK phosphorylation. AMPK activates carnitine palmitoyl transferase 1 (CPT1), which 120 
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transports fatty acids into the mitochondria. Inhibition of CPT1 prevents ghrelin-induced NPY and 121 
AgRP up-regulation [26]. Mitochondrial fatty acid oxidation stimulates uncoupling protein-2 122 
(UCP2) activity, which is an important contributor to the energy capacity of the neuron. GHSR1a-123 
induced activation of the AMPK-CPT1-UCP2 pathway increases AgRP and NPY mRNA 124 
expression by modulating intracellular transcriptional factors, forkhead box O1 (FOXO1) and the 125 
phosphorylated cAMP-response element-binding protein (pCREB), which are translocated to the 126 
nucleus to initiate NPY and AgRP promoter activity, respectively [28-30]. Finally, the transcription 127 
factor, brain-specific homeobox (BSX), interacts with FOXO1 and pCREB to enhance NPY and 128 
AgRP expression [31]. In addition, the transcription factor FOXO1 also suppresses POMC 129 
expression, i.e.: five residues on FOXO1, Gln145, Arg147, Lys148, Arg153 and Arg154, are 130 
necessary to inhibit POMC promoter activity [32]. However, given the low abundance of GSHR1a 131 
on POMC neurons it is unlikely that direct effects of GHSR1a signalling on POMC neurons plays a 132 
significant role in appetite control [26]. On the other hand, suppression of anorexigenic POMC 133 
neurons through inhibitory GABA interactions from NPY and AgRP neurons has potent orexigenic 134 
effects [33]. Overall, GHSR1a stimulates the AMPK-CPT1-UCP2 axis to initiate gene expression 135 
of NPY and AgRP, which suppress anorexigenic POMC neurons through inhibitory GABA 136 
interactions to stimulate appetite [26, 33] (Figure 2).  137 
 138 
2.3 Hypothalamic Circuits Regulating Body Weight: Hypothalamic NPY, AgRP and POMC 139 
neurons of the Arc send projections to second order neurons in several key regions: the 140 
paraventricular nucleus of hypothalamus (PVN), ventromedial nucleus of the hypothalamus 141 
(VMH), dorsomedial hypothalamic nucleus (DMH) and lateral hypothalamus (LH) [34, 35] (Figure 142 
2). For example, the PVN expresses high levels of melanocortin receptor sub-types, 3 and 4 (MC3R 143 
and MC4R) as well as NPY Y1 and Y5 receptors that are involved in appetite regulation by the 144 
diverse afferent inputs (eg: from NPY/AgRP and POMC neurons of the Arc) [36]. The thyrotropin-145 
releasing hormone (TRH) and corticotrophin-releasing hormone (CRH) expressed in the PVN are 146 
also involved in the control of energy balance [37-39]. Elevated Arc NPY expression leads to a 147 
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marked reduction in tyrosine hydroxylase (TH) mRNA and protein expression in the PVN, an effect 148 
that is mediated by Y1 receptors [40]. In the VMH, steroidogenic factor 1 (SF1) and brain-derived 149 
neurotrophic factor (BDNF) play significant roles in the control of energy balance [41-43]. A 150 
number of neuropeptides involved in the control of appetite and energy balance (such as NPY and 151 
CRH) are expressed within the DMH [44]. For example, there is a high level of NPY expression in 152 
the DMH of mice fed a high-fat diet, but this expression is not evident during a normal lab chow 153 
diet [45]. The LH is another region that receives inputs from Arc NPY/AgRP and POMC neurons, 154 
mediating orexigenic responses through orexin and melanin-concentrating hormone (MCH) [45]. In 155 
addition to the hypothalamic nuclei described above, Arc NPY/AgRP and POMC neurons project to 156 
extrahypothalamic areas, including discrete regions of the brainstem (such as the nucleus tractus 157 
solitaries (NTS) via sympathetic noradrenergic (A1 area) and adrenergic (C1 area) innervation, as 158 
well as the parabrachial nucleus (PBN)) to regulate energy intake, BAT thermogenesis, and WAT 159 
lipolysis and lipogenesis [35]. For example, inhibitory GABAergic signalling from NPY/AgRP 160 
neurons to the PBN is crucial in the control of feeding responses [46]. One study reported that acute 161 
ablation of NPY/AgRP/GABA neurons in adult mice using diphtheria toxin (DT) leads to severe 162 
anorexia [47]. Indeed, inactivation of GABA biosynthesis in the Arc or blockade of GABA 163 
receptors in the PBN of mice promotes anorexia [47]. Overall, hypothalamic NPY, AgRP and 164 
POMC neurons induce wide-spread effects on appetite signalling in the brain and metabolic 165 
homeostasis. Therefore, alterations to upstream factors that influence these signals, such as changes 166 
in GHSR1a activity, have significant impact on energy homeostasis and body weight. 167 
 168 
2.4 SGAs increase GHSR1a signalling independent of circulating ghrelin levels – a causal role 169 
in SGA-induced obesity: Circulating ghrelin is increased after olanzapine, clozapine and 170 
risperidone treatment in some individuals with schizophrenia [48, 49]; a result echoed in pre-171 
clinical rodent models [12, 50]. In rats, olanzapine increases plasma ghrelin levels across a range of 172 
dosages [51, 52]. However, the fact that SGA-induced obesity is not always associated with 173 
hyperghrelinemia in humans and rodent models cannot be ignored. Indeed, several studies report 174 
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restored ghrelin homeostasis after 2-weeks of olanzapine and clozapine treatment, even though 175 
weight gain associated with hyperphagia can continue during the first 12 to 16 months of treatment 176 
[53-55]. This result is also observed in the pre-clinical rat model, as plasma ghrelin is increased 177 
after 8 days of olanzapine treatment, but declines to normal levels after 16 days, despite the 178 
continued progression of hyperphagia and weight gain in these rats [12, 50]. Therefore, drug effects 179 
on ghrelin secretion, both directly from its origin in the stomach or indirectly via vagal efferent 180 
commands from the brain [14], cannot be the only mechanism by which SGAs increase 181 
hypothalamic ghrelin signalling and stimulate obesity. We recently reported that olanzapine 182 
increases hypothalamic GHSR1a protein (18-28%) and mRNA (64-92%) expression, independent 183 
of treatment duration [12]. Olanzapine increases hypothalamic GHSR1a expression, and causes 184 
hyperphagia and body weight gain throughout the early (1 day), middle (14 days) and late (36 days) 185 
stages of treatment in rats, even though hyperghrelinaemia is only evident during the early 186 
treatment period [12]. Furthermore, olanzapine increases GHSR1a, phosphorylated AMPK and 187 
NPY, and decreases POMC expression in the hypothalamus [27, 51, 56]. The GHSR1a has an 188 
unusually high level of constitutive activity, ie: can be active in the absence of an agonist [57]. 189 
Therefore, it is possible that up-regulated GHSR1a by olanzapine increases obesogenic signalling 190 
pathways in the hypothalamus independent of circulating ghrelin levels.  191 
 192 
In order to determine whether the increased GHSR1a levels are secondary to the elevated food 193 
intake induced by olanzapine, GHSR1a levels were measured in a pair-feeding experiment, where 194 
food intake of the olanzapine-treated female rats was clamped at the same amount as control rats 195 
[12]. As expected, pair-fed rats did not exhibit body weight differences between olanzapine and 196 
control groups, but olanzapine still increased GHSR1a protein and mRNA expression, and up-197 
regulated levels of NPY and AgRP, as well as their transcription factors FOXO1, pCREB and BSX, 198 
[12]. Therefore, increased GHSR1a and downstream signalling in pair-fed rats, a paradigm that 199 
removes excessive food intake and weight gain as confounding factors, demonstrates a causal role 200 
for GHSR1a upregulation in olanzapine-induced weight gain rather than a consequence of increased 201 
 
Page 9 
food intake or obesity [12]. In addition, direct delivery of a GHSR1a antagonist (D-Lys3-GHRP-6) 202 
to the brain inhibited GHSR1a signalling and prevented olanzapine-induced hyperphagia in rats 203 
[12]. Overall, increased GHSR1a signalling may cause the initial disruption to the primary 204 
hypothalamic appetite signalling pathways (GHSR1a/pAMPK/NPY/AgRP/POMC, Figure 1) that 205 
leads to hyperphagia and obesity during long-term treatment. 206 
 207 
3. The 5-HT2cR and interaction of 5-HT2cR with GHSR1a in SGA-induced obesity 208 
A number of studies have examined the involvement of 5-HT2cR in feeding behaviour. Agonists of 209 
5-HT2cR, lorcaserin and mCPP, decrease food intake [58-60], while antagonists of 5-HT2cR, 210 
RS102221 and TMFPP (a 5-HT2cR and 5-HT1B receptor antagonist) significantly increase food 211 
intake [61]. In addition, obesity and over-eating behaviour has been observed in 5-HT2cR knock-212 
out mice [62].
 
213 
3.1 The 5-HT2cR is associated with SGA-induced obesity: pharmacogenetic and proteomic 214 
evidence. Evidence over the past decade has consistently identified an involvement of the 5-HT2cR 215 
in SGA-induced obesity [reviewed in 63]. Pharmacogenetic studies have revealed that a 5-HT2cR 216 
promoter polymorphism (-759 C/T) is associated with weight gain induced by antipsychotics. For 217 
example, in a sample of Chinese drug-naive schizophrenia patients 22% of subjects carrying the -218 
759T allele had substantially lower weight gain than patients without the allele, following 10 weeks 219 
of treatment with SGAs [64]. Similarly, in a Caucasian group of first episode schizophrenia 220 
patients, the body weight gain in people with the genetic -759 C/T variant allele was also 221 
significantly lower after long-term (9 months) antipsychotic treatment [65]. Some negative reports 222 
have also emerged, in which body weight change after antipsychotic treatment was not related to 5-223 
HT2cR-759C/T polymorphisms [66, 67]. This conflict in findings may be due to previous 224 
polypharmacy or differences in the ethnic origin of the participants, as subjects in one study 225 
included treatment-resistant individuals who had previously received high doses of traditional 226 
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antipsychotics [67], while the other report did not delineate ethnic origin within its sample 227 
population [66].  228 
 229 
Olanzapine and clozapine have potent 5-HT2cR antagonist properties (Kd = 4.8 and 4.1nM) 230 
compared to other SGAs, based on the final concentration of radioligand [68] and the liability of 231 
clozapine and olanzapine-induced weight gain is higher than quetiapine (5-HT2cR Kd = 3500 nM), 232 
risperidone (5-HT2cR Kd = 32 nM) and aripiprazole (a 5-HT2cR partial agonist) [68, 69]. Another 233 
study reported that olanzapine and clozapine have higher 5-HT2cR binding affinities than 234 
haloperidol (Ki = 7.8, 10, >5000 nM for olanzapine, clozapine and haloperidol, respectively) [70]. 235 
5-HT2cR antagonism is correlated with an increased risk of weight gain (rs=45%, p<0.05) and the 236 
morbidity rate associated with Type 2 diabetes mellitus (rs=90%, p<0.05) [71]; a result echoed in 237 
another study reporting that 5-HT2cR affinities for 17 typical and SGA drugs were significantly 238 
correlated with weight gain (rs=-0.49; p<0.05) [72]. We have previously shown that olanzapine 239 
significantly decreases 5-HT2cR binding density in the rat brain, demonstrating a strong effect of 240 
this drug on central 5-HT2cRs [73]. The literature linking 5-HT2C to SGA obesity is vast, but the 241 
causal relationship between 5-HT2cR antagonism and the weight gain liability of SGAs requires 242 
further investigation. We posit that SGA antagonism of the 5-HT2cR disrupts the normal inhibitory 243 
action of this receptor on the GHSR1a, resulting in upregulated orexigenic GHSR1a signalling 244 
pathways (discussed in the section below). 245 
 246 
3.2 5-HT2cR interacts with GHSR1a to reduce GHSR1a signalling and food intake: 247 
Interactions between the serotonin and ghrelin signalling pathways in the brain have been reported 248 
in previous research. For example, GHSR1a activity is inhibited by serotonin, in vivo [17], and 249 
administration of a 5-HT2cR agonist inhibits ghrelin-induced food intake [17, 74]. Decreased 5-250 
HT2cR mRNA expression is observed in GHSR1a knock-out mice, while the acute central 251 
administration of ghrelin increased 5-HT2cR mRNA expression in the amygdala and dorsal raphe 252 
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[75]. Moreover, the intra-hypothalamic administration of serotonin and a 5-HT2cR agonist (2,5-253 
dimethoxy-4-iodoamphetamine) effectively blocked ghrelin’s orexigenic effects in rats [17]. NPY 254 
(the GHSR1a downstream orexigenic signal) is also regulated by the 5-HT2cR, as administration of 255 
the selective 5-HT2cR agonist, WAY-629, suppressed NPY mRNA expression in mice [76]. 256 
Another 5-HT2c/1B receptor agonist, mCPP, decreases NPY secretion in the hypothalamic PVN 257 
and subsequently induced suppression of food intake [77]. Therefore, there is an interaction 258 
between orexigenic GHSR1a, ghrelin, NPY and serotonin 5-HT2cR signalling in the brain, and a 259 
functional effect of 5-HT2cR blockade on appetite through ghrelin signalling. Interestingly, the 5-260 
HT2cR can regulate GHSR1a signalling. The 5-HT2cR interacts with the GHSR1a to form a 261 
heterodimer that inhibits ghrelin signalling [74]. Schellekens and colleagues used flow cytometry 262 
fluorescence resonance energy transfer (fcFRET) to demonstrate the heterodimer between the 263 
GHSR1a and 5-HT2cR in human embryonic kidney (HEK293A) cells [16, 74]. 5-HT2cR and 264 
GHSR1a are also colocalized in rat hypothalamic and hippocampal neurons [74]. Furthermore, we 265 
have found that olanzapine reduces 5-HT2cR and GHSR1a dimerization in a dose-dependent 266 
manner in hypothalamic NPY neurons [78]. The GHSR1a is mainly localized in the plasma 267 
membrane under resting conditions [79]. When exposed to ghrelin, an increase in 5-HT2cR and 268 
GHSR1a dimer co-internalization can occur [16], preventing GHSR1a activity at the cell surface. 269 
Functionally, 5-HT2cR and GHSR1a dimerization decreases GHSR1a-induced intracellular Ca
2+
 270 
signalling, while 5-HT2cR antagonism increases Ca
2+
 signalling [16]. Overall, the GHSR1a 271 
interaction with 5-HT2cR appears to reduce ghrelin signalling that would lead to reduced food 272 
intake. Therefore, 5-HT2cR antagonists (such as obesogenic SGAs) may block the inhibitory effect 273 
of the 5-HT2cR on the GHSR1a to increase orexigenic signalling. Considering the co-localisation 274 
of 5-HT2cR and GHSR1a receptors in multiple hypothalamic nuclei, alterations of the normal 275 
interaction between these receptors may have wide-spread effects in the brain to alter energy 276 
balance [74, 80-82]. 277 
 278 
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Although the existence of a 5-HT2cR and GHSR1a heterodimer has been demonstrated, the exact 279 
molecular interaction between these receptor protein structures is unknown and requires further 280 
investigation. GHSR1a is a GPCR that contains in 15 structural fragments: 7 α-helix hydrophobic 281 
transmembrane (TM I-VII) domains, 6 loops (three intra- and extracellular), and 2 terminal 282 
segments. TM II and III are considered the ligand activation domains. Both endogenous and non-283 
endogenous ligand binding causes a conformational change in the GHSR1a molecular structure, 284 
characterized by a reciprocal rearrangement of the α-helices, with vertical seesaw movements of 285 
TM VI and TM VII around their central proline residues. This alteration can cause the intracellular 286 
ends of TM VI and TM VII to move away from the center of the receptor toward TM III, exposing 287 
the sites subsequently recognized by G-proteins and β-arrestin [83]. The constitutive activity of 288 
GHSR1a is affected by an aromatic cluster formed by three amino acid residues (Phe VI:16, Phe 289 
VII:06, and Phe VII:09) on the inner face of the extracellular ends of GHSR1a TM helices VI and 290 
VII, as reported in a cell-based mutagenesis study [83, 84]. It is the formation of the hydrophobic 291 
core between TM helices VI and VII that ensures proper docking of the extracellular end of TM 292 
helices VII into VI, mimicking agonist activation and stabilizing the receptor in active 293 
conformation. Specific residues in the vicinity of this cluster orchestrate microswitches that are 294 
critical for GHSR1a activation levels in the absence of a ligand (constitutive activity). The 5-295 
HT2cR is also a GPCR with 7 TM helices. Alterations to the amino acid sequence in the editing site 296 
located in the second intracellular loop of the 5-HT2cR produce isoforms of this receptor (Figure 1) 297 
[85-87]. Interestingly, the GHSR1a dimerizes with the unedited 5-HT2cR(INI) isoform, but not 298 
with the partially edited 5-HT2cR (VSV) isoform [16]. Therefore, the 5-HT2cR second intracellular 299 
loop may interact with the GHSR1a transmembrane helices VI and VII to form a heterodimer that 300 
may inhibit the constitutive activity of GHSR1a and subsequent orexigenic signalling. Given that 301 
olanzapine consistently upregulates GHSR1a and is a 5-HT2cR antagonist, blockade of 5-HT2cR 302 
may decrease the normal inhibition of this receptor on the constitutive activity of GHSR1a. It is 303 
conceivable that novel pharmacological agents that target these transmembrane helices, or that 304 
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increase the affinity of the 5-HT2cR to the GSHR1a, may be useful therapies to prevent or attenuate 305 
SGA-induced weight gain side-effects.  306 
 307 
3.3 Use of a 5-HT2cR agonist to prevent / attenuate SGA-induced obesity 308 
The recent U.S. Food and Drug Administration (FDA) approval of the 5-HT2cR receptor agonist 309 
lorcaserin for the treatment of obesity represents a new therapeutic drug class available to the clinic. 310 
A randomized, double-blind, placebo-controlled clinical trial over of 2,200 over-weight and obese 311 
subjects revealed 5-10% weight loss with lorcaserin sustained over 1-year [88]. Lorcaserin (1–312 
2mg/kg SC b.i.d.) treatment for 28 days significantly reduced the percentage of body weight gain 313 
compared to vehicle-treated controls in a diet-induced obese rat model, attributed largely to a 314 
reduction in body fat mass [89]. Lorcaserin is also effective at attenuating ghrelin-induced food 315 
intake in mice [74], demonstrating a potential interaction between lorcaserin and the ghrelin 316 
signalling system. Furthermore, a case study reported weight loss with lorcaserin in a schizophrenia 317 
patient treated with olanzapine [90]; however, the mechanisms are unknown and further studies are 318 
required. The potent 5-HT2cR antagonist property of olanzapine could be responsible for disrupting 319 
the normal inhibitory tone of the 5-HT2cR on the GHSR1aby reducing inhibitory 5-320 
HT2cR/GHSR1a interactions (Figure 2). Interestingly, another 5-HT2cR agonist, vabicaserin, 321 
recently demonstrated antipsychotic efficacy in a Phase II trial of schizophrenia patients, with no 322 
weight gain and minimal extrapyramidal side-effects [91]. Therefore, co-treatment of olanzapine 323 
with a 5-HT2cR agonist (lorcaserin or vabicaserin) is a promising novel possibility for restoring 5-324 
HT2cR activity and preventing the initial disruption to GHSR1a-induced appetite signalling caused 325 
by olanzapine. In addition, POMC neurons also regulate food intake and express 5-HT2cR. Only 326 
8% POMC neurons express GHSR1a suggesting that 5-HT2cR can regulate POMC independent of 327 
GHSR1a. The anti-obesity effect of 5-HT2cR agonist may involve both hypothalamic NPY and 328 
POMC neurons, but via different mechanism. In addition, there is no literature reporting the effect 329 
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of obesogenic antipsychotic drugs on genetic mutant mouse models on 5-HT2cR and GHSR1a, 330 
which may help to verify the specificities of these receptors in SGA-induced obesity. 331 
 332 
4. Concluding Remarks and Future Perspectives 333 
Both antagonism of serotonin 5-HT2cR and activation of GHSR1a signalling have been identified 334 
as the main causes of SGA-induced obesity. Activation of the GHSR1a plays an important role in 335 
SGA-induced obesity through intracellular signalling pathways (AMPK-CPT1-UCP2) that increase 336 
orexigenic NPY and AgRP, and suppress anorexigenic POMC signalling in the hypothalamus [23, 337 
25, 26]. The 5-HT2cR plays a pivotal regulatory role in ghrelin-mediated appetite signalling. The 5-338 
HT2cR dimerizes with the GHSR1a to inhibit its orexigenic activity, while 5-HT2cR antagonism 339 
reduces the dimerization and increases GHSR1a-induced food intake [16, 74]. Obesogenic SGAs, 340 
including olanzapine, clozapine, and risperidone, possesses potent 5-HT2cR antagonist properties 341 
[92]. Therefore, 5-HT2cR antagonism by SGAs may disinhibit the GHSR1a to increase orexigenic 342 
signalling. Unfortunately, the molecular mechanisms linking 5-HT2cR antagonism and GHSR1a in 343 
SGA-induced obesity remain unclear. The constitutive activity of GHSR1a is highly influenced by 344 
an aromatic cluster on the inner face of the extracellular ends of TM helices VI and VII [83]. The 345 
residues of the 5-HT2cR in the editing cassette located in the second intracellular loop of 5-HT2cR 346 
[85] may interact with this cluster to inactivate its conformation. Further investigation into this 347 
mechanism is warranted. In addition, combined treatment of a 5-HT2cR agonist with SGAs may 348 
restore inhibitory control of GHSR1a by the 5-HT2cR. Lorcaserin, a FDA approved anti-obesity 5-349 
HT2cR receptor agonist drug, attenuates ghrelin-induced food intake [74]. Therefore, co-treatment 350 
of SGAs with lorcaserin may prevent the disruption to GHSR1a-induced appetite signalling caused 351 
by SGAs. In summary, antagonism of the 5-HT2cR by SGAs may reduce GHSR1a interaction with 352 
the 5-HT2cR and activate ghrelin signalling to stimulate feeding behavior. The 5-HT2cR and its 353 
interaction with GHSR1a could be clinically relevant for the treatment of SGA-induced obesity and 354 
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a valuable target for the design of new compounds that remove 5-HT2cR antagonist properties of 355 
SGAs to prevent obesity.  356 
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Figure legends: 594 
 595 
Figure 1. Schematic drawing of ghrelin signalling pathway and interaction with 5-HT2cR in 596 
the hypothalamus. Ghrelin binds to the ghrelin receptor (GHSR1a), triggering phosphorylation of 597 
5’ AMP-activated protein kinase (AMPK) that activates carnitine palmitoyl transferase 1 (CPT1), 598 
subsequent fatty acid shuttling into the mitochondria and uncoupling protein-2 (UCP2) activity. 599 
Transcriptional factors, forkhead box O1 (FOXO1) and phospho-cAMP-response element binding 600 
protein (pCREB) translocate to the nucleus and bind to their response element on the DNA. Brain-601 
specific homeobox (BSX) interacts with FOXO1 and pCREB to initiate expression of neuropeptide 602 
Y (NPY) and agouti-related peptide (AgRP). The serotonin 5-HT2c receptor (5-HT2cR) is a G 603 
protein-coupled receptor with seven transmembrane domains. The 2
nd
 intracellular loop contains an 604 
editing site. At this site, three amino residues (shown as red dots) can exist in an unedited state (5-605 
HT2cR-INI isoform) or a partially edited state (5-HT2cR-VSV isoform) that either enables or 606 
prevents heterodimer formation (for example with the GHSR1a), respectively. The unedited 5-607 
HT2cR-INI isoform can form a heterodimer with the GHSR1a transmembrane helices VI and VII 608 
that inhibits this orexigenic signalling pathway. 609 
 610 
Figure 2. The primary mechanism of antipsychotics-induced obesity. This figure depicts how 611 
second generation antipsychotics (SGAs) affect the hypothalamic circuit in regulating body weight. 612 
The ghrelin receptor (GHSR1a) is expressed on NPY/AgRP neurons of the Arc, the PVN and 613 
VMH. GHSR1a orexigenic signalling is inhibited by serotonin 2c receptors (5-HT2cR) through 614 
heterodimerisation (described in Figure 1). SGAs are 5-HT2cR antagonists and blockade of this 615 
receptor may release inhibition of hypothalamic GHSR1a signalling. Given the complexity of 616 
hypothalamic appetite signalling, alterations in signalling in this region would have wide-spread 617 
effects on multiple systems and physiological outcomes leading to body weight gain and obesity 618 
side-effects. Abbreviations: neuropeptide Y (NPY), agouti-related peptide (AgRP), pro-619 
opiomelanocortin (POMC),gamma-Aminobutyric acid (GABA), melanocortin 3 and 4 (MC3 and 620 
MC4), α melanocortin-stimulating hormone (α MSH), tryrotropin- and corticotropin-releasing 621 
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hormones (TSH and CRH), steroidogenic factor 1 (SF1), brain-derived neurotrophic factor (BDNF), 622 
melanin-concentrating hormone (MCH). paraventricular nucleus (PVN), ventromedial 623 
hypothalamus (VMH), dorsomedial hypothalamic nucleus (DMH), lateral hypothalamus (LH), 3
rd
 624 
ventricle (3V), arcuate nucleus (Arc), nucleus tractus solitarius (NTS), parabrachial nucleus (PBN), 625 
sympathetic nervous system (SNS), brown adipose tissue (BAT), white adipose tissue (WAT). 626 
 627 
 628 
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